TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06626347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TREAT-ED Virtual Group Diabetes Self-Management Education and Support
Description: TREAT-ED is an innovative group telehealth delivery model designed to engage emerging adults in DSMES services. TREAT-ED sessions are facilitated by a Diabetes Care and Education Specialist and include content centered around the ADCES7 Self-Care Behaviors and applied learning strategies, e.g., case scenarios integrating glucose monitoring, and group discussions to drive knowledge transfer and skill development for diabetes self-care behaviors within the context of issues that are salient to the target population.
Study: NCT06686589

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal ultrasound
Description: Intestinal ultrasound performed by hand held ultrasound devices
Study: NCT06690060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Intervention
Description: The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
Study: NCT06695949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation
Description: Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
Study: NCT05588063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device will appear to function but no electrical stimulation will be delivered.
Study: NCT06072339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound for PEEP setting
Description: NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation session
Description: The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation session
Description: The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood gas
Description: Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arterial blood gas
Description: Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview on pain and comfort
Description: The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview on pain and comfort
Description: The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
Study: NCT06432985

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling (Cognitive Behavioral Therapy, CBT)
Description: Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Counseling (Cognitive Behavioral Therapy, CBT)
Description: Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TUD Treatment as Usual (TAU)
Description: Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
Study: NCT06695949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous neuromodulation
Description: Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
Study: NCT06686667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The intervention arm will consist of a time-restricted eating protocol with fasting between 11:00 PM to 6:00 AM. Ad libitum eating will be allowed outside these times and the protocol will be administered during day and night shifts over a 2 week period.
Study: NCT06694896

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microarray Application
Description: Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.
Study: NCT06695741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
Study: NCT05475938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Painting therapy and psychoanalysis
Description: Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
Study: NCT04563520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPCC-emicizumab
Description: Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, routine prophylaxis to prevent or reduce the frequency of bleeding episodes. If there is less than a good' response in bleed event at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with a max dose of no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
Study: NCT06501924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DA-005
Description: Oral Botanical Supplement HIF-1a inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil 5%
Description: Topical minoxidil 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-002
Description: Topical Alpha 1 Agonist (GRAS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT06686498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery adapted to suicidal behavior (IMR-ACS)
Description: Illness Management and Recovery adapted to suicidal behavior (IMR-ACS) is a protocolized clinical intervention in a brief group format aimed at people at risk of suicide. Specifically, people who have had more than two attempts in their lifetime are called repeaters. For its construction, we relied on the Spanish version of the Illness Management and Recovery IMR, developed by the Spanish Nursing Association, adapted to the field of suicidal behavior, taking as a reference the model of personal recovery from suicide attempt proposed by Sokol et al.~The goals of IMR-ACS are to 1) know the warning signs of a suicidal crisis, 2) implement strategies to manage the suicidal crisis, 3) foster social support among peers, 4) formulate goals for recovery from a suicidal crisis, and 5) seek help and make informed decisions in the event of a suicidal crisis.~IMR-ACS is a complementary intervention to the usual treatments.
Study: NCT06691763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention for stress management and health promotion
Description: Pythagorean Self-Awareness is a holistic stress magement program that combines cognitive reconstruction and the implementation of the 6 pillars of life-style medicine depending on the targeted population.
Study: NCT06691516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal and vertical bone augmentation using computer guided cortical shell technique
Description: Computer-guided cortical shell technique in anterior mandible 3d defect using bone harvesting guide and fixation guides

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free hand cortical shell technique in anterior 3d defect
Description: vertical and horizontal ridge augmentation in anterior mandible using free hand cortical shell technique
Study: NCT06070532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
Description: 100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
Study: NCT06501924

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Topical Solution
Description: Placebo Topical Solution
Study: NCT05968638

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: Regular Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: Ketogenic Diet
Study: NCT05192486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-038
Description: Administration by intravenous infusion
Study: NCT05986188

Intervention type: OTHER
Intervention: Pathways to Potential
Description: Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
Study: NCT05243251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine 5 MG
Description: , Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
Study: NCT00013195

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Care
Study: NCT06397261

Intervention type: DEVICE
Intervention: LarynGuide
Description: Artificial Intelligence assisted tracheal video intubation
Study: NCT06248320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigh ventilation
Description: Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
Study: NCT06417307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Maintain daily lifestyle until the end of the study. Receive no intervention/supplements.
Study: NCT05606614

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TSHA-102
Description: TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TSHA-102
Description: TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
Study: NCT05945732

Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.
Study: NCT06292299

Intervention type: DEVICE
Intervention: Pneumowave
Description: Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring (e.g. CR-PSG)

Intervention type: DEVICE
Intervention: Pneumowave
Description: Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring (e.g. CR-PSG)
Study: NCT05607459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Dry Needling
Description: For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin.
Study: NCT05847686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participate in therapy visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05954988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTI-03
Description: Caveolin-1-Scaffolding-Protein-Derived Peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTI-03
Description: Caveolin-1-Scaffolding-Protein-Derived Peptide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05346562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabidiol-matched placebo tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabidiol-matched placebo tablets
Study: NCT04345939

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection method
Description: Different methods for pathogen diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection method
Description: Different methods for pathogen diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection method
Description: Different methods for pathogen diagnosis
Study: NCT06513195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound-guided portal pressure measurement
Description: The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
Study: NCT05964738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics withdrawal
Description: Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics maintenance
Description: Any diuretic could be used